1
|
Lee JH, Yuk JM, Cha GH, Lee YH. Expression of cytokines and co-stimulatory molecules in the Toxoplasma gondii-infected dendritic cells of C57BL/6 and BALB/c mice. PARASITES, HOSTS AND DISEASES 2023; 61:138-146. [PMID: 37258260 DOI: 10.3347/phd.22150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Accepted: 03/14/2023] [Indexed: 06/02/2023]
Abstract
Toxoplasma gondii is an intracellular protozoan parasite which can infect most warm-blooded animals and humans. Among the different mouse models, C57BL/6 mice are more susceptible to T. gondii infection compared to BALB/c mice, and this increased susceptibility has been attributed to various factors, including T-cell responses. Dendritic cells (DCs) are the most prominent type of antigen-presenting cells and regulate the host immune response, including the response of T-cells. However, differences in the DC responses of these mouse strains to T. gondii infection have yet to be characterized. In this study, we cultured bone marrow-derived DCs (BMDCs) from BALB/c and C57BL/6 mice. These cells were infected with T. gondii. The activation of the BMDCs was assessed based on the expression of cell surface markers and cytokines. In the BMDCs of both mouse strains, we detected significant increases in the expression of cell surface T-cell co-stimulatory molecules (major histocompatibility complex (MHC) II, CD40, CD80, and CD86) and cytokines (tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-12p40, IL-1β, and IL-10) from 3 h post-T. gondii infection. The expression of MHC II, CD40, CD80, CD86, IFN-γ, IL-12p40, and IL-1β was significantly higher in the T. gondii-infected BMDCs obtained from the C57BL/6 mice than in those from the BALB/c mice. These findings indicate that differences in the activation status of the BMDCs in the BALB/c and C57BL/6 mice may account for their differential susceptibility to T. gondii.
Collapse
Affiliation(s)
- Jae-Hyung Lee
- Department of Medical Science and Department of Infection Biology, Chungnam National University College of Medicine, Daejeon 35015, Korea
| | - Jae-Min Yuk
- Department of Medical Science and Department of Infection Biology, Chungnam National University College of Medicine, Daejeon 35015, Korea
| | - Guang-Ho Cha
- Department of Medical Science and Department of Infection Biology, Chungnam National University College of Medicine, Daejeon 35015, Korea
| | - Young-Ha Lee
- Department of Medical Science and Department of Infection Biology, Chungnam National University College of Medicine, Daejeon 35015, Korea
| |
Collapse
|
2
|
Ramírez L, de Moura LD, Mateus NLF, de Moraes MH, do Nascimento LFM, de Jesus Melo N, Taketa LB, Catecati T, Huete SG, Penichet K, Piranda EM, de Oliveira AG, Steindel M, Barral-Netto M, do Socorro Pires e Cruz M, Barral A, Soto M. Improving the serodiagnosis of canine Leishmania infantum infection in geographical areas of Brazil with different disease prevalence. Parasite Epidemiol Control 2020; 8:e00126. [PMID: 31832561 PMCID: PMC6890974 DOI: 10.1016/j.parepi.2019.e00126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 11/19/2019] [Indexed: 01/31/2023] Open
Abstract
Serodiagnosis of Leishmania infantum infection in dogs relies on the detection of antibodies against leishmanial crude extracts or parasitic defined antigens. The expansion of canine leishmaniasis from geographical areas of Brazil in which the infection is endemic to regions in which the disease is emerging is occurring. This fact makes necessary the analysis of the serodiagnostic capabilities of different leishmanial preparations in distinct geographical locations. In this article sera from dogs infected with Leishmania and showing the clinical form of the disease, were collected in three distinct Brazilian States and were tested against soluble leishmanial antigens or seven parasite individual antigens produced as recombinant proteins. We show that the recognition of soluble leishmanial antigens by sera from these animals was influenced by the geographical location of the infected dogs. Efficacy of the diagnosis based on this crude parasite preparation was higher in newly endemic regions when compared with areas of high disease endemicity. We also show that the use of three of the recombinant proteins, namely parasite surface kinetoplastid membrane protein of 11 kDa (KMP-11), and two members of the P protein family (P2a and P0), can improve the degree of sensitivity without adversely affecting the specificity of the diagnostic assays for canine leishmaniasis, independently of the geographical area of residence. In addition, sera from dogs clinically healthy but infected were also assayed with some of the antigen preparations. We demonstrate that the use of these proteins can help to the serodiagnosis of Leishmania infected animals with subclinical infections. Finally, we propose a diagnostic protocol using a combination of KMP-11, P2a y P0, together with total leishmanial extracts.
Collapse
Key Words
- Antibodies
- BB, blocking buffer
- CanL, Canine visceral leishmaniasis
- Canine leishmaniasis
- EDCB, ELISA denaturant coating buffer
- ELISA, enzyme-linked immunosorbent assay
- HSP, Heat shock protein
- KMP-11, Kinetoplastid-membrane protein of 11 kDa
- LR, Likelihood ratio
- Leishmania
- MS, Mato Grosso do Sul State (Brazil)
- PBS, phosphate saline buffer
- PI, Piaui State (Brazil)
- ROC, Receiver Operating Characteristic
- RR, Relative reactivity
- RT, Room temperature
- Recombinant proteins
- SC, Santa Catarina State (Brazil)
- SLA, Soluble leishmanial antigen
- Serodiagnosis
- VL, Visceral leishmaniosis
- WB, Washing buffer
Collapse
Affiliation(s)
- Laura Ramírez
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Luana Dias de Moura
- Centro de Ciências Agrárias, Universidade Federal do Piaui (UFPI), Teresina, 64049-550 PI, Brazil
| | - Natalia Lopes Fontoura Mateus
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Milene Hoehr de Moraes
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | | | - Nailson de Jesus Melo
- Centro de Ciências Agrárias, Universidade Federal do Piaui (UFPI), Teresina, 64049-550 PI, Brazil
| | - Lucas Bezerra Taketa
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Tatiana Catecati
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | - Samuel G. Huete
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Karla Penichet
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | - Eliane Mattos Piranda
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Alessandra Gutierrez de Oliveira
- Laboratório de Parasitologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul (UFMS), Cidade Universitária, s/n, Campo Grande 79070-900 MS, Brazil
| | - Mario Steindel
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Santa Catarina (UFSC), Florianópolis 88040-900 SC, Brazil
| | - Manoel Barral-Netto
- Centro de Pesquisas Gonçalo Moniz (Fundação Oswaldo Cruz- FIOCRUZ). Waldemar Falcão, 121, Salvador 40296-710 BA, Brazil
| | | | - Aldina Barral
- Centro de Pesquisas Gonçalo Moniz (Fundação Oswaldo Cruz- FIOCRUZ). Waldemar Falcão, 121, Salvador 40296-710 BA, Brazil
| | - Manuel Soto
- Centro de Biología Molecular Severo Ochoa (CBMSO), Departamento de Biología Molecular, Facultad de Ciencias, CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
| |
Collapse
|
3
|
Iborra S, Solana JC, Requena JM, Soto M. Vaccine candidates against leishmania under current research. Expert Rev Vaccines 2018; 17:323-334. [PMID: 29589966 DOI: 10.1080/14760584.2018.1459191] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
INTRODUCTION The search for vaccines to prevent human leishmaniasis is an active field of investigation aimed to prevent the devastating effects of this family of diseases on human health. The design and commercialization of several vaccines against canine leishmaniasis is a hopeful advance toward the achievement of a human vaccine. AREAS COVERED This review includes a summary of the most relevant immunological aspects accompanying leishmaniasis in natural hosts as well as a description of the latest advances in the multiple strategies that are being followed to develop leishmanial prophylactic vaccines. We have combined citations of the latest specialized reviews with research articles presenting the most recent results. EXPERT COMMENTARY Achieving safe, effective, durable and low-cost prophylactic vaccines against leishmaniasis is still a major challenge. These vaccines should control not only parasite progression, but also the accompanying pathology, which results from an imbalanced interaction between the infectious agent and the human host immune system. Different strategies for development of vaccines are currently under investigation. They range from the use of live non-pathogenic vectors to the employment of subunit vaccines combined with adjuvants and/or delivery systems inducing cell-mediated immunity.
Collapse
Affiliation(s)
- Salvador Iborra
- a Department of Vascular Biology and Inflammation Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Immunobiology of Inflammation Laboratory , Madrid , Spain.,b School of Medicine , Universidad Complutense de Madrid , Madrid , Spain
| | - José Carlos Solana
- c Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Departamento de Biología Molecular, Nicolás Cabrera 1 , Universidad Autónoma de Madrid , Madrid , Spain
| | - José María Requena
- c Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Departamento de Biología Molecular, Nicolás Cabrera 1 , Universidad Autónoma de Madrid , Madrid , Spain
| | - Manuel Soto
- c Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Departamento de Biología Molecular, Nicolás Cabrera 1 , Universidad Autónoma de Madrid , Madrid , Spain
| |
Collapse
|
4
|
Garde E, Ramírez L, Corvo L, Solana JC, Martín ME, González VM, Gómez-Nieto C, Barral A, Barral-Netto M, Requena JM, Iborra S, Soto M. Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis. Front Cell Infect Microbiol 2018; 8:112. [PMID: 29675401 PMCID: PMC5895769 DOI: 10.3389/fcimb.2018.00112] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 03/21/2018] [Indexed: 02/05/2023] Open
Abstract
Different members of intracellular protein families are recognized by the immune system of the vertebrate host infected by parasites of the genus Leishmania. Here, we have analyzed the antigenic and immunogenic properties of the Leishmania eIF2 and eIF2B translation initiation factors. An in silico search in Leishmania infantum sequence databases allowed the identification of the genes encoding the α, β, and γ subunits and the α, β, and δ subunits of the putative Leishmania orthologs of the eukaryotic initiation factors F2 (LieIF2) or F2B (LieIF2B), respectively. The antigenicity of these factors was analyzed by ELISA using recombinant versions of the different subunits. Antibodies against the different LieIF2 and LieIF2B subunits were found in the sera from human and canine visceral leishmaniasis patients, and also in the sera from hamsters experimentally infected with L. infantum. In L. infantum (BALB/c) and Leishmania major (BALB/c or C57BL/6) challenged mice, a moderate humoral response against these protein factors was detected. Remarkably, these proteins elicited an IL-10 production by splenocytes derived from infected mice independently of the Leishmania species employed for experimental challenge. When DNA vaccines based on the expression of the LieIF2 or LieIF2B subunit encoding genes were administered in mice, an antigen-specific secretion of IFN-γ and IL-10 cytokines was observed. Furthermore, a partial protection against murine CL development due to L. major infection was generated in the vaccinated mice. Also, in this work we show that the LieIF2α subunit and the LieIF2Bβ and δ subunits have the capacity to stimulate IL-10 secretion by spleen cells from naïve mice. B-lymphocytes were identified as the major producers of this anti-inflammatory cytokine. Taking into account the data found in this study, it may be hypothesized that these proteins act as virulence factors implicated in the induction of humoral responses as well as in the production of the down-regulatory IL-10 cytokine, favoring a pathological outcome. Therefore, these proteins might be considered markers of disease.
Collapse
Affiliation(s)
- Esther Garde
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Laura Ramírez
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Laura Corvo
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - José C. Solana
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - M. Elena Martín
- Departamento de Bioquímica-Investigación, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Víctor M. González
- Departamento de Bioquímica-Investigación, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Carlos Gómez-Nieto
- Parasitology Unit, LeishmanCeres Laboratory, Veterinary Faculty, University of Extremadura, Cáceres, Spain
| | - Aldina Barral
- Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz-FIOCRUZ, Salvador, Brazil
| | - Manoel Barral-Netto
- Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz-FIOCRUZ, Salvador, Brazil
| | - José M. Requena
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Salvador Iborra
- Immunobiology of Inflammation Laboratory, Department of Vascular Biology and Inflammation, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Department of Immunology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
- Health Research Institute (imas12), Ciudad Universitaria, Madrid, Spain
- *Correspondence: Salvador Iborra
| | - Manuel Soto
- Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain
- Manuel Soto
| |
Collapse
|
5
|
Pirdel L, Zavaran Hosseini A. Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB/c mice. Parasite Immunol 2017; 39. [PMID: 27353355 DOI: 10.1111/pim.12345] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 06/20/2016] [Indexed: 01/06/2023]
Abstract
Development of a protective antileishmanial vaccine is an urgent priority for successful control of different forms of leishmaniasis. The potential of a recombinant lipophosphoglycan 3 (rLPG3) expressed by Leishmania tarentolae was evaluated in combination with CpG oligodeoxynucleotides (CpG-ODN) as a Th1-promoting adjuvant against Leishmania infantum infection in BALB/c mice. First, mice were immunized subcutaneously with rLPG3 either alone or in combination with CpG-ODN. Next, the immunogenic and protective efficacies of this vaccine were analysed in immunized mice. It was observed that coadministration of rLPG3 with CpG-ODN led to enhance in a Th1 response to rLPG3 induced by itself as the IFN-γ production was promoted in association with the predominant presence of IgG2a antibodies in the sera. However, immunization with rLPG3 plus CpG-ODN induced partial protection against infectious challenge in BALB/c mice. Taken together, further studies are required to improve the protective efficacy using either more potent immune enhancers or vaccination strategies.
Collapse
Affiliation(s)
- L Pirdel
- Department of Medical Sciences, Ardabil Branch, Islamic Azad University, Ardabil, Iran
| | - A Zavaran Hosseini
- Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| |
Collapse
|
6
|
Whitlock GC, Robida MD, Judy BM, Qazi O, Brown KA, Deeraksa A, Taylor K, Massey S, Loskutov A, Borovkov AY, Brown K, Cano JA, Magee DM, Torres AG, Estes DM, Sykes KF. Protective antigens against glanders identified by expression library immunization. Front Microbiol 2011; 2:227. [PMID: 22125550 PMCID: PMC3221416 DOI: 10.3389/fmicb.2011.00227] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2011] [Accepted: 10/26/2011] [Indexed: 11/21/2022] Open
Abstract
Burkholderia are highly evolved Gram-negative bacteria that primarily infect solipeds but are transmitted to humans by ingestion and cutaneous or aerosol exposures. Heightened concern over human infections of Burkholderia mallei and the very closely related species B. pseudomallei is due to the pathogens' proven effectiveness as bioweapons, and to the increased potential for natural opportunistic infections in the growing diabetic and immuno-compromised populations. These Burkholderia species are nearly impervious to antibiotic treatments and no vaccine exists. In this study, the genome of the highly virulent B. mallei ATCC23344 strain was examined by expression library immunization for gene-encoded protective antigens. This protocol for genomic-scale functional screening was customized to accommodate the unusually large complexity of Burkholderia, and yielded 12 new putative vaccine candidates. Five of the candidates were individually tested as protein immunogens and three were found to confer significant partial protection against a lethal pulmonary infection in a murine model of disease. Determinations of peripheral blood cytokine and chemokine profiles following individual protein immunizations show that interleukin-2 (IL-2) and IL-4 are elicited by the three confirmed candidates, but unexpectedly interferon-γ and tumor necrosis factor-α are not. We suggest that these pathogen components, discovered using genetic immunization and confirmed in a conventional protein format, will be useful toward the development of a safe and effective glanders vaccine.
Collapse
Affiliation(s)
- Gregory C. Whitlock
- Department of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA
| | - Mark D. Robida
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - Barbara M. Judy
- Department of Pathology, University of Texas Medical BranchGalveston, TX, USA
| | - Omar Qazi
- Institute for Cellular and Molecular Biology, University of TexasAustin, TX, USA
| | - Katherine A. Brown
- Institute for Cellular and Molecular Biology, University of TexasAustin, TX, USA
- Department of Chemistry and Biochemistry, University of TexasAustin, TX, USA
| | - Arpaporn Deeraksa
- Department of Pathology, University of Texas Medical BranchGalveston, TX, USA
| | - Katherine Taylor
- Department of Pathology, University of Texas Medical BranchGalveston, TX, USA
| | - Shane Massey
- Department of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA
- Department of Pathology, University of Texas Medical BranchGalveston, TX, USA
| | - Andrey Loskutov
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - Alex Y. Borovkov
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - Kevin Brown
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - Jose A. Cano
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - D. Mitchell Magee
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
| | - Alfredo G. Torres
- Department of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA
- Department of Pathology, University of Texas Medical BranchGalveston, TX, USA
- Sealy Center for Vaccine Development, University of Texas Medical BranchGalveston, TX, USA
| | - D. Mark Estes
- Department of Microbiology and Immunology, University of Texas Medical BranchGalveston, TX, USA
| | - Kathryn F. Sykes
- Center for Innovations in Medicine in the Biodesign Institute, Arizona State UniversityTempe, AZ, USA
- School of Life Sciences, Arizona State UniversityTempe, AZ, USA
| |
Collapse
|
7
|
Benitez A, Priest JW, Ehigiator HN, McNair N, Mead JR. Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine 2011; 29:9239-45. [PMID: 21968447 DOI: 10.1016/j.vaccine.2011.09.094] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2011] [Revised: 09/18/2011] [Accepted: 09/23/2011] [Indexed: 10/17/2022]
Abstract
The Cryptosporidium parvum acidic ribosomal protein P2 (CpP2) is an important immunodominant marker in C. parvum infection. In this study, the CpP2 antigen was evaluated as a vaccine candidate using a DNA vaccine model in adult C57BL/6 IL-12 knockout (KO) mice, which are susceptible to C. parvum infection. Our data show that subcutaneous immunization in the ear with DNA encoding CpP2 (CpP2-DNA) cloned into the pUMVC4b vector induced a significant anti-CpP2 IgG antibody response that was predominantly of the IgG1 isotype. Compared to control KO mice immunized with plasmid alone, CpP2-immunized mice demonstrated specific in vitro spleen cell proliferation as well as enhanced IFN-γ production to recombinant CpP2. Further, parasite loads in CpP2 DNA-immunized mice were compared to control mice challenged with C. parvum oocysts. Although a trend in reduction of infection was observed in the CpP2 DNA-immunized mice, differences between groups were not statistically significant. These results suggest that a DNA vaccine encoding the C. parvum P2 antigen is able to provide an effective means of eliciting humoral and cellular responses and has the potential to generate protective immunity against C. parvum infection but may require using alternative vectors or adjuvant to generate a more potent and balanced response.
Collapse
Affiliation(s)
- Alvaro Benitez
- Emory University School of Medicine, Department of Pediatrics, Atlanta, GA, USA
| | | | | | | | | |
Collapse
|
8
|
Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. INFECTION GENETICS AND EVOLUTION 2010; 9:1075-82. [PMID: 19805015 DOI: 10.1016/j.meegid.2009.02.009] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2008] [Revised: 02/17/2009] [Accepted: 02/19/2009] [Indexed: 10/21/2022]
Abstract
Trypanosoma cruzi and the genus Leishmania are protozoan parasites causing diseases of major public health importance, and the recent completion of the sequencing of their genomes has opened new opportunities to further our understanding of the mechanisms required for protection and the development of vaccines. For example, trans-sialidases, one of the largest protein families from T. cruzi, contain dominant CD8+ T cell epitopes, and their use as preventive or therapeutic vaccines in different animal models has provided encouraging results. A much wider range of antigens and vaccine formulations have been tested against Leishmania, and new correlates for protection are being defined, such as the induction of multifunctional Th1 effector cells capable of producing a complex set of cytokines. Also, while a large number of these vaccine candidates have been rather successful in mouse models, their usefulness in more relevant animal models is still poor, in spite of significant immunogenicity. Novel proteomics and genomics approaches are being used for antigen discovery and the identification of new vaccine candidates, some of which have shown promise for the control of infection. These studies cast little doubt that T. cruzi and Leishmania genomes represent major resources for understanding key aspects of the mechanisms of immune protection against these parasites, and the increasing use of these tools will greatly impact vaccine development.
Collapse
Affiliation(s)
- Eric Dumonteil
- Laboratorio de Parasitología, Centro de Investigaciones Regionales Dr Hideyo Noguchi, Universidad Autónoma de Yucatán, Merida, Yucatan, Mexico
| |
Collapse
|
9
|
Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int 2009; 58:319-24. [DOI: 10.1016/j.parint.2009.07.013] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2009] [Revised: 07/28/2009] [Accepted: 07/31/2009] [Indexed: 11/24/2022]
|
10
|
Araújo MSS, de Andrade RA, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Vianna LR, Mayrink W, Reis AB, Malaquias LCC, Mello MN, Martins-Filho OA. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune®. Vaccine 2009; 27:1008-17. [DOI: 10.1016/j.vaccine.2008.11.104] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2008] [Revised: 11/26/2008] [Accepted: 11/28/2008] [Indexed: 11/29/2022]
|
11
|
Launois P, Tacchini-Cottier F, Kieny MP. Cutaneous leishmaniasis: progress towards a vaccine. Expert Rev Vaccines 2008; 7:1277-87. [PMID: 18844599 DOI: 10.1586/14760584.7.8.1277] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Leishmaniases are vector-borne diseases due to the protozoan parasite Leishmania . Since no prevention method is available and as current therapy is costly, often poorly tolerated and not always efficacious, the development of alternative therapies, including vaccines, constitutes the priority in the fight of Leishmania infection. This review focuses on recent advances in the development of vaccines against leishmaniasis, with emphasis on the cutaneous form. Indeed, the fact that recovery from leishmaniasis is associated with immunity against new infection provides a rational basis for the development of vaccination strategy against infection with Leishmania . Evidence from animal studies demonstrate that protection can be achieved following infection with live-attenuated Leishmania as well as through immunization with purified proteins or DNA vaccines. In addition, recent results have shown that immunization against the saliva of the insect vector could have synergistic effects with conventional vaccination. Finally, vaccination using dendritic cells was recently demonstrated as a possible tool for Leishmania vaccination.
Collapse
Affiliation(s)
- Pascal Launois
- WHO-Immunology Research and Training Center, Department of Biochemistry, University of Lausanne, Chemin des Boveresses, 155, CH-1066 Epalinges, Switzerland.
| | | | | |
Collapse
|
12
|
Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 2008; 112:1832-43. [PMID: 18577706 PMCID: PMC2518890 DOI: 10.1182/blood-2007-12-130138] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The clinical outcomes of dendritic cell (DC)-based immunotherapy remain disappointing, with DCs often displaying a tenuous capacity to complete maturation and DC1 polarization in the tumor host. Surprisingly, we observed that the capacity for successful DC1 polarization, including robust IL12p70 production, could be regulated by STAT-dependent events even prior to DC differentiation. Exposure of CD34(pos) cells to single-agent granulocyte-macrophage colony-stimulating factor (GMCSF) induced multilineage, STAT5-dependent differentiation, including DCs that failed to mature in the absence of further exogenous signals. In contrast, Flt3L induced nearly global differentiation of CD34(pos) cells into spontaneously maturing DCs. IL-6 synergized with Flt3L to produce explosive, STAT3-dependent proliferation of phenotypically undifferentiated cells that nevertheless functioned as committed DC1 precursors. Such precursors not only resisted many tumor-associated immunosuppressants, but also responded to tumor contact or TGFbeta with facilitated DC maturation and IL12p70 production, and displayed a superior capacity to reverse tumor-induced T-cell tolerance. GMCSF preempted Flt3L or Flt3L plus IL-6 licensing by blocking STAT3 activation and promoting STAT5-dependent differentiation. Paradoxically, following overt DC differentiation, STAT5 enhanced whereas STAT3 inhibited DC1 polarization. Therefore, nonoverlapping, sequential activation of STAT3 and STAT5, achievable by sequenced exposure to Flt3L plus IL-6, then GMCSF, selects for multilog expansion, programming, and DC1 polarization of tumor-competent DCs from CD34(pos) cells.
Collapse
Affiliation(s)
- Peter A Cohen
- Center for Surgery Research, Cleveland Clinic Foundation/Lerner Research Institute, OH 44195, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Pais FS, DaRocha WD, Almeida RM, Leclercq SY, Penido ML, Fragoso SP, Bartholomeu DC, Gazzinelli RT, Teixeira SM. Molecular characterization of ribonucleoproteic antigens containing repeated amino acid sequences from Trypanosoma cruzi. Microbes Infect 2008; 10:716-25. [DOI: 10.1016/j.micinf.2008.03.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2008] [Revised: 03/10/2008] [Accepted: 03/14/2008] [Indexed: 11/16/2022]
|